Clinical Trial Results: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Gadoquatrane to an existing MRI contrast agent, evaluating efficacy and safety in patients with non-brain/spinal cord pathologies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-enhanced Magnetic Resonance Imaging
• Non-central Nervous System Pathology

Drugs mentioned

• Gadoquatrane (gadoquatrane)

Snippet

Sponsor: Bayer | Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology | Phase 3 | Status: COMPLETED | Results posted: 2026-08-20